Department of Neurology, The First People's Hospital of Lianyungang/ Department of Neurology, The First Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang, Jiangsu Province 222000, China.
Department of Emergency Medicine, The First People's Hospital of Lianyungang/ Department of Neurology, The First Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang, Jiangsu Province 222000, China.
Dis Markers. 2020 Aug 1;2020:8895900. doi: 10.1155/2020/8895900. eCollection 2020.
Family with sequence similarity 19 member A5 (FAM19A5), a novel chemokine-like peptide, is a secreted protein mainly expressed in the brain. FAM19A5 was recently found to be involved in a variety of neurological diseases; however, its correlation with vascular dementia (VaD) remains unclear. The aim of the study is to explore the association between serum FAM19A5 and cognitive impairment in subjects with VaD.
136 VaD subjects and 81 normal controls were recruited in the study. Their demographic and clinical baseline data were collected on admission. All subjects received Mini-Mental State Examination (MMSE) evaluation, which was used to test their cognitive functions. A sandwich enzyme-linked immunosorbent assay (ELISA) was applied to detect the serum levels of FAM19A5.
No significant differences were found between the two groups regarding the demographic and clinical baseline data ( > 0.05). The serum FAM19A5 levels were significantly higher compared to normal controls ( < 0.001). The Spearman correlation analysis indicated that serum FAM19A5 levels and MMSE scores have a significant negative correlation in VaD patients ( = -0.414, <0.001). Further multiple regression analysis indicated that serum FAM19A5 levels were independent risk predictors for cognitive functions in VaD ( = 0.419, = 0.031).
The serum FAM19A5 level of VaD patients is significantly increased, which may serve as a biomarker to predict cognitive function of VaD.
家族序列相似性 19 成员 A5（FAM19A5）是一种新型趋化因子样肽，主要在脑中表达，是一种分泌蛋白。最近发现 FAM19A5 参与多种神经疾病，但与血管性痴呆（VaD）的相关性尚不清楚。本研究旨在探讨 VaD 患者血清 FAM19A5 与认知障碍的相关性。
本研究纳入了 136 例 VaD 患者和 81 名正常对照者。入院时收集了他们的人口统计学和临床基线数据。所有患者均接受了简易精神状态检查（MMSE）评估，用于测试他们的认知功能。采用夹心酶联免疫吸附试验（ELISA）检测血清 FAM19A5 水平。
两组间人口统计学和临床基线数据无显著差异（>0.05）。与正常对照组相比，VaD 患者的血清 FAM19A5 水平显著升高（<0.001）。Spearman 相关分析表明，VaD 患者的血清 FAM19A5 水平与 MMSE 评分呈显著负相关（=−0.414，<0.001）。进一步的多元回归分析表明，血清 FAM19A5 水平是 VaD 患者认知功能的独立危险因素（=0.419，=0.031）。
VaD 患者的血清 FAM19A5 水平显著升高，可能作为预测 VaD 认知功能的生物标志物。
